Pain and bladder dysfunction in an animal model of multiple sclerosis

H. Cavaleiro 1,*, R. Silva 2, R. Oliveira 1,2,3, A. Coelho 1,2,3, F. Cruz 2,3,4, C.D. Cruz 1,2,3
1 Department Biomedicine – Experimental Biology Unit, Faculty of Medicine, Porto, Portugal
2 Translational NeuroUrology Group, Instituto de Investigação e Inovação em Saúde, Porto, Portugal
3 Instituto de Biologia Molecular e Celular, Porto, Portugal
4 Dept. of Urology Hospital São João, Porto, Portugal
E-mail address: helenacavaleiro@hotmail.com (H. Cavaleiro).

Aim: Here, we investigated if MS-induced pain and bladder dysfunction can be attenuated by TRPV1 desensitization with RTX.

Introduction: Multiple sclerosis (MS) is the most prevalent neurological disorder in young people, causing irreversible disability and producing substantial economic and social impact. Among the most incapacitating symptoms, neuropathic pain and bladder dysfunction are reported by the majority of patients. The transient receptor potential vanilloid 1 (TRPV1) is a receptor described to have an important role in neuropathic pain, bladder dysfunction and inflammation. TRPV1 desensitization with agonists, such as resiniferatoxin (RTX), has been shown to improve bladder function and reduce behavioural signs of pain in various animal models of disease. In the context of MS, a recent study showed that TRPV1 knockout mice were protected from disease progressions, presenting delayed disease onset, myelin preservation and reduced clinical scores.

Methods: Experimental Auto-immune Encephalitis (EAE) was induced by a single injection in the flank of a solution of myelin basic protein (MBP) in Complete Freund’s adjuvant (CFA). Behavioural tests were performed to evaluate symptoms. One month after MS-induction, animals were anesthetized and cystometries performed. Two other groups of MS animals received intrathecal RTX or vehicle and also submitted to behavioural tests and cystometries. At end of experiments, tissue was collected and processed.

Results: EAE rats developed neuropathic pain, as shown by the presence of mechanical allodynia and hypersensitivity to thermal stimuli. Cystometries performed at this point showed signs of neurogenic detrusor overactivity. These clinical signs were accompanied by decreased spinal expression of MBP and increased activity of astrocytes and microglia. Preliminary observations suggest that intrathecal RTX improved cutaneous hypersensitivity and bladder function. These results suggest that TRPV1 might be involved in pain bladder dysfunction accompanying MS and that its modulation could have therapeutic relevance.

Conclusion: These results suggest that TRPV1 might be involved in pain bladder dysfunction accompanying MS and that its modulation could have therapeutic relevance.

http://dx.doi.org/10.1016/j.pbj.2017.07.071
Introduction: Despite the well-established successful use of BoNTs to treat a variety of human conditions, their mechanism of action is still not fully understood. Thus, there is an emergent need of new and accurate models to study the effects of BoNTs. However, considering their potential lethality, it is challenging to find reproducible models to study the local application of BoNTs in living animals that allow a widespread visualization of the intoxicated nerve terminals.

In these work, we studied the innervation pattern and the effect of BoNTs in a group of small subcutaneous cranial muscles that are responsible for moving the pinna in rodents. Although all are easily accessible and manipulated, we focused on the levator auris longus (LAL).

Methods: Animals were injected subcutaneously with the indicated doses of BoNT/A, in the cranial muscles area. Muscles were then dissected and prepared for wholemount staining for Synapsin-I, cleaved SNAP-25 (synaptosome-associated protein of 25 kDa) and β3-tubulin.

Results: Detection of cleaved SNAP-25, the end-product of the catalytic action of BoNT/A, was possible even with injections as low as 0.1 ng. Mapping of the injected muscle showed the effect of BoNT/A in the majority of the endplate population. Also, seven days after BoNT/A injection, a sprouting process was evident, a landmark of regeneration.

Conclusion: BoNTs delivery to the LAL is a sensitive, simple and reproducible model to study the mechanisms of action of these toxins as it allowed the evaluation of BoNT/A effects throughout the entire muscle, without sampling bias. Thus, we forward that the LAL manipulation may constitute an excellent model to clarify the mechanisms of action of BoNTs in the neuromuscular system.

Acknowledgements: This study has been funded by FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 - Operational Program for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT – Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274).

http://dx.doi.org/10.1016/j.pbj.2017.07.074

PS188

NLRP3 inflammasome as a potential target to reduce epileptic-like activity


Faculdade de Medicina, Universidade de Lisboa e Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal

E-mail address: leonor_rr@hotmail.com (L. Ribeiro-Rodrigues).

Aim: Decipher how inflammation drives epilepsy and how NLRP3 targeting impacts epileptic-like activity.

Introduction: Epilepsy is one of the most common neurological diseases in worldwide. Inflammation was linked to the presence of inflammasomes, cytosolic multiprotein complexes, which promote the release of proinflammatory cytokines, namely IL-1β. Although a feedback loop has been described between inflammation and epilepsy, the role of inflammasomes in epilepsy is still unknown. NLRP3 is the most studied inflammasome, activated by a two-signal process: 1) a priming signal (as lipopolysaccharides – LPS), which enhances the expression of NLRP3 and pro-IL-1β; and 2)